Motley Fool: 3 Popular Marijuana Stocks With Surprisingly Poor Margins

According to a newly released report from the duo of Arcview Market Research and BDS Analytics titled “State of the Legal Cannabis Markets,” global cannabis sales could grow in excess of 24% per year through 2024. After registering $10.9 billion…

Advertisements

Motley Fool: Why Canopy, Aurora, and Aphria Stocks Fell up to 20% in May — and How They’re Faring in June

What happened Along with nearly all cannabis stocks, Canopy Growth (NYSE:CGC), Aurora Cannabis (NYSE:ACB), and Aphria (NYSE:APHA) cratered last month. Stocks of these three top Canadian growers plunged 20.3%, 16.4%, and 13.6%, respectively, according to data from S&P Global Market Intelligence.…

Motley Fool: 3 Marijuana Stocks Where Investors Have Lost Faith in Management

Although it’s still very early in the legalization process, marijuana offers the potential of being a once-in-a-lifetime growth opportunity. After racking up only $5.4 billion in global legal sales in 2015, Cowen Group analyst Vivien Azer foresees $75 billion in…

Motley Fool: Health Canada Is Tackling the Marijuana Shortage With This Game-Changing Move

Pardon the cliche, but the marijuana industry appears to be the greatest thing since sliced bread. Although the cannabis industry has existed for decades behind the scenes, the legalization of recreational weed in Canada, along with more than 40 countries…

Motley Fool: 2 Healthcare Stocks Ripe for a Takeover

The healthcare sector has a well-earned reputation for ultra-pricey acquisitions. In 2017, for example, Gilead Sciences paid nearly $12 billion for Kite Pharma and its commercially unproven cell therapy platform. Kicking off this year, Bristol-Myers Squibb struck a $74 billion deal to…